CN104997816B - Improve the pine pollen composition and application thereof of gastrointestinal function - Google Patents
Improve the pine pollen composition and application thereof of gastrointestinal function Download PDFInfo
- Publication number
- CN104997816B CN104997816B CN201510471077.1A CN201510471077A CN104997816B CN 104997816 B CN104997816 B CN 104997816B CN 201510471077 A CN201510471077 A CN 201510471077A CN 104997816 B CN104997816 B CN 104997816B
- Authority
- CN
- China
- Prior art keywords
- pollen
- broken
- pollen pini
- natural
- pini
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 235000008331 Pinus X rigitaeda Nutrition 0.000 title claims abstract description 14
- 235000011613 Pinus brutia Nutrition 0.000 title claims abstract description 14
- 241000018646 Pinus brutia Species 0.000 title claims abstract description 14
- 230000007661 gastrointestinal function Effects 0.000 title abstract description 23
- 241000018650 Pinus massoniana Species 0.000 claims abstract description 65
- 235000011609 Pinus massoniana Nutrition 0.000 claims abstract description 53
- 239000000463 material Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 11
- 230000006872 improvement Effects 0.000 claims abstract description 8
- 230000000295 complement effect Effects 0.000 claims abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 19
- 230000002496 gastric effect Effects 0.000 claims description 18
- 230000013872 defecation Effects 0.000 claims description 16
- 235000011610 Pinus tabuliformis Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000030136 gastric emptying Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 210000000936 intestine Anatomy 0.000 abstract description 15
- 230000006870 function Effects 0.000 abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 abstract description 7
- 230000002503 metabolic effect Effects 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 230000029087 digestion Effects 0.000 abstract description 3
- 230000007717 exclusion Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 206010010774 Constipation Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 13
- 239000000976 ink Substances 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- -1 regulator Substances 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 210000001809 melena Anatomy 0.000 description 5
- 230000008855 peristalsis Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010006326 Breath odour Diseases 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 208000032139 Halitosis Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229960004192 diphenoxylate Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000218641 Pinaceae Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- ANERHPOLUMFRDC-UHFFFAOYSA-K bismuth citrate Chemical class [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ANERHPOLUMFRDC-UHFFFAOYSA-K 0.000 description 1
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- GJYLKIZKRHDRER-UHFFFAOYSA-N calcium;sulfuric acid Chemical compound [Ca].OS(O)(=O)=O GJYLKIZKRHDRER-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to nutrition, health food and field of medicine preparations.The purpose of the present invention is to provide the pine pollen compositions that a kind of effect more preferably improves gastrointestinal function.Broken masson pine pollen and the natural pollen pini of non-broken wall are specifically applied in combination by a certain percentage, then adds the dosage form that pharmaceutically acceptable auxiliary material or complementary ingredient are prepared.Broken pollen and natural pollen are applied in combination the present invention, have the function of synergistic, expansion using face.Broken masson pine pollen is more advantageous to the release and absorption of effective component, can improve utilization of the body to pollen pini nutriment, is conducive to effective component and is absorbed into blood rapidly, reaches lesion and plays pharmacodynamics effect.Natural pollen pini dietary fiber abundant can not only improve intestine microenvironment, moreover it is possible to promote digestion waste and the exclusion of other metabolic toxicities, be conducive to the recovery and improvement of gastrointestinal function.The combination of broken masson pine pollen and natural pollen pini would be even more beneficial to pollen pini and play the effect for adjusting gastrointestinal function.
Description
Technical field
The present invention relates to nutrition, health food and field of medicine preparations, more particularly to a kind of adjusting gastrointestinal function
Pine pollen composition and preparation method thereof.
Background technique
Gastrointestinal tract is important digestive organs, human body to maintain normal physiological biochemical function, immune function, growth and development and
The vital movements such as metabolism just must provide main energy sources by the food of pipe intestinal digesting.Gastronintestinal system passes through food
Intake, transhipment, digestion and absorption and the activity such as excretion of residue be human body power supply, in addition, gastronintestinal system still has part
Endocrine and immune function.The diversification of gastrointestinal system function determines that the imbalance of gastrointestinal function and decline will all cause one
The obvious clinical symptoms of series.Specifically main includes three aspects: (1) paralysis of stomach caused by gastrointestinal motility disorder and paralysis
Property intestinal obstruction etc.；(2) ulcer and inflammation etc. caused by normal mucosa defencive function is impaired；(3) malabsorption and dyssecretosis institute
Cause diarrhea, constipation etc..The normal of gastrointestinal function is of great significance for maintenance body other function, raw however as the modern times
The change of quickening, dietary structure that movable joint is played and the rising of competitive pressure, enterogastric diseases disease incidence just rises year by year at present.
The product position of most of recuperating gastrointestinal tract function is all more single currently on the market, such as the weak, intestines for WeiDongLi Capsule
The monotherapy such as road hypoperistalsis, flora imbalance, gastrointestinal ulceration, although there is certain curative effect, attends to one thing and lose sight of another, can not be entirely square
Position comprehensively regulating.For portioned product even there are also some serious toxic side effects, such as many relax bowel and defecation products all contain rheum officinale, reed
The more strong drug such as luxuriant growth, folium sennae can also cause some toxicitys to react while improving clinical symptoms, and using face is inevitable
It is subject to certain restrictions.
Pollen pini is the male sex-cell of pinaceae plant masson pine, Chinese pine or other congeners, is that pinaceae plant passes
Ancestor connects the substance in generation.Pollen pini protein rich in, 21 kinds of amino acid, carbohydrate (carbohydrate), lipid are (especially rich
Rich polyunsaturated fatty acid), nearly hundred kinds of organized enzymes, 10 multivitamins, more than 50 kinds of macro- and trace-elements, more than 10 kinds of flavones
And 200 plurality of active ingredients such as carrotene, nucleic acid, polysaccharide, phytosterol, auxin, and nutrition-allocated proportion balances, and it is contained
Nutriment it is comprehensive with balanced in nature there are no any wholefoods to match in excellence or beauty therewith.With in recent years to pine
Many pharmacological actions of pollen more in-depth study, pollen pini are found.According to current documents and materials, pollen pini, which mainly has, exempts from
Epidemic disease adjusting, antifatigue, antitumor, free radical resisting, regulating lipoid and reducing blood pressure adjust blood glucose, are liver protecting, resistance prostatitis, anti-radiation, beautiful
The effects of holding beauty treatment, recuperating gastrointestinal tract.Its gastrointestinal tract adjustment effect is especially prominent in the numerous pharmacological action of pollen, flower
Powder energy is comprehensive, multiple target point adjusts gastrointestinal function, so that gastrointestinal function is restored to normal level, is mainly manifested in following three
Aspect:
1) enhance gastroenteritic power, promote emptying: research shows that digestive ferment abundant can whet the appetite in pollen pini, being promoted
Level of serum gastrin enhances WeiDongLi Capsule, promotes gastric emptying, improves pipe intestinal digesting ability.Pollen pini can also stimulate enteron aisle
The movement of smooth muscle promotes intestines peristalsis, can significantly improve constipation symptom.
2) gastrointestinal mucosa is protected, enhance absorption of nutrient ingredients: experimental study shows that pollen pini can significantly improve gastrointestinal tract
Mucous membrane condition in damaged inhibits gastrointestinal tract inflammation.The flavones contained in pollen pini has significant anti-oxidative stress, can reduce
Radical reaction, to play the above effect, furthermore the substances such as amino acid abundant, vitamin also contribute to being damaged in pollen pini
The reparation and the gastrointestinal inflammatory development of inhibition of mucous membrane.
3) improve environment in stomach and intestine, reduce the accumulation of metabolic toxicities: the imbalance of gastrointestinal tract microenvironment may cause various aspects
Symptom, such as diarrhea, constipation, acne, halitosis.Pollen pini dietary fiber rich in such as pectic substance, lignin, fiber
Element can stimulate intestines peristalsis to promote defecation.Insoluble diedairy fiber can absorb large quantity of moisture, can increase defecation volume and excrement
Moisture content, these are all conducive to relief of constipation symptom, while the exclusion of stool alleviates the accumulation of organism metabolism toxin, can be into
The symptoms such as acne, halitosis caused by one step is alleviated because of gastrointestinal dysfunction.Experimental study also shows that pollen pini is able to maintain that enteron aisle
Colony balance can significantly improve the symptoms such as diarrhea caused by flora imbalance, indigestion.
Pollen pini is with its nutriment abundant and its comprehensive pharmacodynamics effect in terms of recuperating gastrointestinal tract function, for exploitation
Completely new gastrointestinal tract conditioning products provide direction.Preserved egg powder have thicker cell wall, this make wherein effective component it is molten
Out slowly, experiment in vitro research shows that in broken masson pine pollen the dissolution of effective component be significantly faster than that non-broken masson pine pollen.Therefore, mesh
It is raw material that preceding pollen pini product most of in the market, which all uses broken pollen, this is not have for the product for developing pollen other function
It is influential, or even play the role of some beneficial.
But the present inventor studies for a long period of time, the pollen pini of broken wall finds broken the opsonic action of gastrointestinal function
Wall pollen pini is not necessarily best in terms of recuperating gastrointestinal tract function.
Summary of the invention
The purpose of the present invention is to provide the pine pollen compositions that a kind of effect more preferably improves gastrointestinal function.Tool
Body is broken masson pine pollen and the natural pollen pini of non-broken wall to be applied in combination by a certain percentage as main active, then adds pharmacy
The preparation that upper acceptable auxiliary material or complementary ingredient are prepared.
Technical solution of the present invention: the raw material comprising following weight proportion is that the suitable clinic that active constituent is prepared makes
Preparation:
6-25 parts of broken masson pine pollen, natural pollen pini 10-30 parts.
The pharmaceutically acceptable complementary ingredient, it has certain physiological activity, but the addition of the ingredient will not change
Become the leading position of aforementioned pharmaceutical compositions in the course of disease treatment, and only play auxiliary effect, these auxiliary effects are only
It is only the utilization to the ingredient known activity, is the usual adjuvant treatment modality of field of medicaments.
The broken masson pine pollen is the pollen pini of 95% or more sporoderm-broken rate.
The natural pollen pini be masson pine, Chinese pine and other belong to one of pollen or a variety of.
As preferred embodiments of the present invention, it is raw material such as comprising lower weight proportion plus pharmaceutically acceptable auxiliary material
The preparation for the suitable clinical use being prepared:
10-20 parts of broken masson pine pollen, natural pollen pini 14-25 parts.
Further, it is that the raw material comprising following weight proportion is fitted plus what pharmaceutically acceptable auxiliary material was prepared
Close the preparation of clinical use:
12 parts of broken masson pine pollen, 16 parts of natural pollen pini.
Wherein the broken masson pine pollen be broken wall masson pine, Chinese pine and other belong to pollen through breaking-wall cell treated flower
It is one or more in powder.
The natural pollen pini be masson pine, Chinese pine and other belong to pure natural pollen of the pollen without any working process
One of or it is a variety of.
It is that the natural pollen pini is natural Pollen of Masson Pine as preferred embodiments of the present invention, is secondly Chinese pine pollen.
It is that the broken masson pine pollen is broken wall Pollen of Masson Pine as preferred embodiments of the present invention, is secondly Chinese pine pollen.
The present invention also provides the preparation methods of above-mentioned composition, it includes following operating procedure:
Broken masson pine pollen and natural pollen pini is taken to combine mixing according to the ratio, in addition pharmaceutically acceptable auxiliary material or complementary
Ingredient is prepared into pharmaceutically common formulations.
The present invention also provides above-mentioned pine pollen compositions in preparation improvement gastrointestinal function and because gastrointestinal function is lacked of proper care
Caused by purposes in related symptoms drug.
Further, the improvement gastrointestinal function refers to enhancing WeiDongLi Capsule, promotes gastric emptying, promote intestines peristalsis, protect
Protect gastrointestinal tract mucous, inhibition gastrointestinal ulceration, adjust micro ecology of gastrointestinal tract environment etc..
Further, related symptoms caused by improving because of gastrointestinal function imbalance refer to because of functional disturbances of gastrointestinal tract or decline
The manifest symptom of clinical observable caused by moving back.As because flatulence caused by gastric dynamic dysfunction, it is inverse vomit, sour regurgitation；Because gastrointestinal mucosa damages
Gastroenteritic ulcer, gastrointestinal bleeding etc. caused by wound；Acne, halitosis because caused by constipation accumulates internal metabolic toxicities, because of stomach
Diarrhea, abdominal pain, intestinal colic caused by intestine microenvironment is unbalance etc..
Further, the drug refer to enhancing WeiDongLi Capsule, promote gastric emptying, inhibit gastroenteritic ulcer, protection gastrointestinal mucosa,
Relax bowel and defecation, the drug for improving intestinal microecology.
Broken masson pine pollen and natural pollen pini are applied in combination the present invention, have the function of synergistic, expansion using face.
Broken masson pine pollen is more advantageous to the release and absorption of effective component, can improve utilization of the body to pollens nutrition substance, be conducive to
Effective component is absorbed into rapidly blood, reaches lesion and plays pharmacodynamics effect.Natural pollen pini dietary fiber abundant can not only
Improve intestine microenvironment, moreover it is possible to promote digestion waste and the exclusion of other metabolic toxicities, be conducive to the extensive of gastrointestinal function
Multiple and improvement.It is better that the improvement of intestine microenvironment and the timely removing of metabolic waste, toxin are all conducive to gastrointestinal tract
The function of digesting and assimilating is played, being absorbed and utilized for pollen pini nutriment is thus more advantageous to.Therefore, broken masson pine pollen and day
The effect that pollen pini plays adjusting gastrointestinal function that would be even more beneficial to is used in combination in right pollen pini.
Below by way of specific embodiment, the present invention is described in further detail, but is not intended to limit the present invention, ability
Field technique personnel are variously modified and replace according to the present invention, and as long as it does not depart from the spirit of the invention, should belong to the present invention
Scope of the appended claims.
Specific embodiment
The Pollen Assemblage object provided by the invention for improving gastrointestinal function includes that the raw material of following weight proportion is prepared
Suitable clinical use preparation:
6-25 parts of broken masson pine pollen, natural pollen pini 10-30 parts.
The broken masson pine pollen is natural pollen pini through conventional broken wall treatment, and the sporoderm-broken rate of pollen pini is made to reach 95% or more
Pollen pini.For example, being dried to moisture 6% hereinafter, then zero after natural pollen being rinsed with water, being impregnated 2-5 hours
Freeze rapidly under the conditions of lower 30 DEG C, is carried out broken wall treatment 10-20 minutes through low temperature concussion micronizer, broken wall can be obtained
The broken masson pine pollen of 95% or more rate.It is of course also possible to buy the broken masson pine pollen of commercially available 95% or more sporoderm-broken rate.
In addition, the present invention also can control the technology for broken wall of pollen pini, so that the sporoderm-broken rate of pollen pini is in range appropriate,
Reach the ratio of broken masson pine pollen and non-broken masson pine pollen in the scope of the present invention, achieves the object of the present invention.
The natural pollen pini be masson pine, Chinese pine and other belong to one of pollen or a variety of.
As preferred embodiments of the present invention, it is the preparation that the raw material comprising following weight proportion is prepared:
10-20 parts of broken masson pine pollen, natural pollen pini 14-25 parts.
Further, it is the preparation that the raw material comprising following weight proportion is prepared:
12 parts of broken masson pine pollen, 16 parts of natural pollen pini.
Wherein the broken masson pine pollen be masson pine, Chinese pine and other belong to pollen through in breaking-wall cell treated pollen
It is one or more.
The natural pollen pini be masson pine, Chinese pine and other belong to one of pollen or a variety of.
It is that the natural pollen pini is natural Pollen of Masson Pine as preferred embodiments of the present invention, is secondly Chinese pine pollen.
It is that the broken masson pine pollen is broken wall Pollen of Masson Pine as preferred embodiments of the present invention, is secondly Chinese pine pollen.
Pharmaceutically acceptable auxiliary material of the present invention includes but are not limited to filler (diluent), lubricant (helps stream
Agent or antitack agent), dispersing agent, wetting agent, adhesive, regulator, solubilizer, antioxidant, bacteriostatic agent, emulsifier, disintegrating agent
Deng.Adhesive include syrup, Arabic gum, gelatin, sorbierite, tragacanth, cellulose and its derivates (such as microcrystalline cellulose,
Sodium carboxymethylcellulose, ethyl cellulose or hypromellose etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidine
Ketone etc.；Filler includes lactose, Icing Sugar, dextrin, starch and its derivative, cellulose and its derivates, inorganic calcium salt (such as sulfuric acid
Calcium, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate etc.), sorbierite or glycine etc.；Lubricant includes superfine silica gel powder, stearic acid
Magnesium, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol etc.；Disintegrating agent includes starch and its derivative (such as carboxylic
Methyl starch sodium, Explotab, pregelatinized starch, modified starch, hydroxypropul starch, cornstarch etc.), polyvinyl pyrrole
Alkanone or microcrystalline cellulose etc.；Wetting agent includes lauryl sodium sulfate, water or alcohol etc.；Antioxidant packages contain sodium sulfite, sulfurous
Sour hydrogen sodium, sodium pyrosulfite, dibutyl benzoic acid etc.；Bacteriostatic agent includes 0.5% phenol, 0.3% cresols, 0.5% anesin
Deng；Regulator includes hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer (including phosphoric acid dioxy sodium and phosphoric acid hydrogen
Disodium) etc.；Emulsifier includes Tween-80, does not have that sour sorb is smooth, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.；Solubilising
Agent includes Tween-80, bile, glycerol etc..
The pharmaceutically acceptable complementary ingredient, it has certain physiological activity, but the addition of the ingredient will not change
Become the leading position of aforementioned pharmaceutical compositions in the course of disease treatment, and only play auxiliary effect, these auxiliary effects are only
It is only the utilization to the ingredient known activity, is the usual adjuvant treatment modality of field of medicaments.Such as on the basis of the present invention
It adds with probiotics, the Bismuth Potassium Citrate with protection gastrointestinal mucosa effect, tripotassium for improving gastrointestinal bacterial flora structure
Two bismuth citrates etc. assist functional component.
Those skilled in the art are readily apparent that the active constituent of the present composition can also cooperate the treatment of current routine
The drugs such as gastroenteritic ulcer, constipation, diarrhea are used together.
Wherein, the dosage form is through gastrointestinal tract absorption type.For example, tablet, powder, pill, capsule, granule or mouth
Take liquid.
The present invention also provides above-mentioned pine pollen compositions in preparation improvement gastrointestinal function and because gastrointestinal function is lacked of proper care
Caused by purposes in related symptoms drug.
Further, the improvement gastrointestinal function refers to enhancing WeiDongLi Capsule, promotes gastric emptying, promote intestines peristalsis, protect
Protect gastrointestinal tract mucous, inhibition gastrointestinal ulceration, adjust micro ecology of gastrointestinal tract environment etc..
Further, related symptoms caused by improving because of gastrointestinal function imbalance refer to because of functional disturbances of gastrointestinal tract or decline
The manifest symptom of clinical observable caused by moving back.As because flatulence caused by gastric dynamic dysfunction, it is inverse vomit, sour regurgitation；Because gastrointestinal mucosa damages
Gastroenteritic ulcer, gastrointestinal bleeding etc. caused by wound；Acne, halitosis because caused by constipation accumulates internal metabolic toxicities, because of stomach
Diarrhea, abdominal pain, intestinal colic caused by intestine microenvironment is unbalance etc..
Further, the drug refer to enhancing WeiDongLi Capsule, promote gastric emptying, inhibit gastroenteritic ulcer, protection gastrointestinal mucosa,
Relax bowel and defecation, the drug for adjusting intestinal microecology.
The following are specific examples.
Embodiment 1
6 parts of broken masson pine pollen, 11 parts of natural pollen pini, the above raw material combine mixing according to the ratio, add microcrystalline cellulose, carboxylic
The pharmaceutically acceptable auxiliary material such as sodium carboxymethylcellulose pyce, magnesium stearate is prepared into tablet.
Embodiment 2
12 parts of broken masson pine pollen, 14 parts of natural pollen pini, combination mixes according to the ratio, in addition superfine silica gel powder, magnesium stearate etc.
Pharmaceutically acceptable auxiliary material is prepared into capsule.
Embodiment 3
8 parts of broken masson pine pollen, 12 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at suspension type oral solution.
Embodiment 4
12 parts of broken masson pine pollen, 16 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at granule.
Embodiment 5
10 parts of broken masson pine pollen, 18 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at granule.
Embodiment 6
14 parts of broken masson pine pollen, 16 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at granule.
Embodiment 7
6 parts of broken masson pine pollen, 30 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at tablet.
Embodiment 8
20 parts of broken masson pine pollen, 25 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at powder.
Embodiment 9
15 parts of broken masson pine pollen, 28 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at granule.
Embodiment 10
12 parts of broken masson pine pollen, 20 parts of natural pollen pini, combination mixes according to the ratio, in addition pharmaceutically acceptable auxiliary material system
For at granule.
Pharmacodynamic experiment
1. the influence of pair mice with constipation
1.1 material
Kunming mouse (male and female dual-purpose, weight 18-20g), prepared Chinese ink, the present composition, broken masson pine pollen, natural preserved egg
Powder, compound diphenoxylate.
1.2 method
(1) be grouped: mouse is normally raised 5 days after buying back and is observed, without exception, selects 50 healthy mices and divides at random
At 5 groups, i.e., normal group, model group, broken masson pine pollen group, natural pollen pini group, present composition group (by embodiment 4 prepare
Broken wall+natural pollen pini group).
(2) dosage and administration route: oral stomach-filling, stomach-filling volume are 0.2ml/10g weight, and blank control group is given
The distilled water of amount.A weight of animals is claimed to adjust stomach-filling amount every other day.It was calculated according to pollen pini conventional amount used 3-6g/ days, in test
With adult (60kg), dosage 6g is calculated daily, and being converted to mouse bioequivalence dosage is daily 900mg/kg.
(3) modeling: taking R-1132 50mg (20), is ground with mortar and adds distilled water to be settled in after powder
100ml, for manufacturing Constipation Model.Experimental measuring is every mouse stomach-filling 0.2ml/10g weight, that is, 10mg/kg weight.Respectively
Stomach-filling laboratory sample, model group and Normal group distinguish stomach-filling normal salt to experimental group respectively in addition to handling according to model group
Water.
(4) testing index:
A Intestinal pushing functional experiment: after continuous gavage gives each group mouse difference tested material 14d, fasting 16h is during which free
Drinking-water.The compound diphenoxylate of 10mg/kg is given in stomach-filling respectively for Constipation Model group and three test groups.Negative control group is to consubstantiality
Product physiological saline.After 30min, the prepared Chinese ink suspension containing corresponding tested material is given in three test group stomach-fillings, negative control group and
Model group stomach-filling blank prepared Chinese ink, row cervical dislocation puts to death animal after 25min, take out rapidly mouse stomach and whole section of ileocecus position
Small intestine is not added traction and is directly laid on blank sheet of paper after gently removing, measurement Length of intestine is " total small intestinal length ", from pylorus to prepared Chinese ink
The distance in forward position is that prepared Chinese ink promotes length, and Intestinal propulsive rate (%) is calculated according to the following formula:
The experiment of B mouse defecation: mouse difference tested material is given in stomach-filling, and each group stool in mice character is observed during raising.It fills
14d after stomach, fasting are drunk water 16 hours.10mg/kg compound diphenoxylate is given in Constipation Model group and three test group stomach-fillings, right
Same volume physiological saline is given according to group.After 30min, the prepared Chinese ink suspension containing corresponding tested material is given in each test group stomach-filling, negative
Blank prepared Chinese ink is given in control group and model group stomach-filling.The equal single cage raising normal water feed of animal.The timing since prepared Chinese ink stomach-filling,
Record every animal clap the first grain melena time, defecation grain number and weight in 5h.
1.3 test results and analysis
Influence (n=10) of the 1 different disposal pollen pini of table to mouse small intestine propulsion rate
| Group | Total small intestinal length | Prepared Chinese ink promotes length | Ink progradation |
| Normal group | 58.68±8.24 | 35.12±5.74 | 60.16±8.50 |
| Model group | 59.84±4.21 | 25.46±5.76 | 42.38±8.86## |
| Broken masson pine pollen group | 57.62±6.55 | 28.44±6.66 | 53.31±7.06* |
| Natural pollen pini group | 54.82±3.55 | 33.08±4.23 | 59.47±4.31** |
| Present composition group | 56.04±4.30 | 42.68±6.32 | 76.86±6.88** |
The P compared with normal group##< 0.01, the P compared with model group*< 0.05, P**< 0.01
Influence (n=10) of 2 pollen pini of table to each defecation index of mouse
| Group | The just time non-for the first time | Defecation grain number in 5h | Defecation weight in 5h |
| Normal group | 115.6±12.8 | 24.6±8.8 | 0.79±0.12 |
| Model group | 187±21.7## | 11.2±2.3## | 0.28±0.11## |
| Broken pollen group | 162±16.2* | 20.1±2.8** | 0.45±0.14** |
| Natural pollen group | 141±11.8** | 24.7±1.9** | 0.58±0.12** |
| The present composition | 123±12.6** | 30.5±4.7** | 0.69±0.16** |
The P compared with normal group##< 0.01, the P compared with model group*< 0.05, P**< 0.01
Model group mouse small intestine ink progradation is significantly lower than Normal group it can be seen from upper table 1, shows mouse just
Secret model foundation success, each medicine-feeding test group can increase mice with constipation small intestine ink progradation, exist compared with model group aobvious
Work or extremely significant difference.It is the most significantly wherein the present composition, is secondly natural pollen pini group, is again broken wall pine
Pollen.As can be seen that comparing with normal group, the model group small mouse's head grain melena time is obviously prolonged table 2,5 hours melena quantity and
Weight significantly reduces, and illustrates modeling success.Three test groups, which are observed, can shorten the time that mice with constipation arranges first grain melena, increase
Add 5 hours row's melena quantity and weight, wherein the most obvious with present composition group.
The experimental result observed above may be related with the loss of the dietary fiber of broken masson pine pollen.Contain in pollen pini
The water-soluble dietary fibers such as pectin, soluble polysaccharide, oligosaccharide in enteron aisle at solution state, there is preferable retention ability,
And solution, by enteric bacteria glycolysis, enteron aisle can be reduced by generating short chain fatty acids, these short chain fatty acids such as butyric acid, propionic acid, acetic acid
Interior environmental pH, stimulation intestinal mucosa are wriggled.The carbon dioxide that is generated after furthermore water-soluble dietary fiber is fermented by intestinal flora,
The gases such as hydrogen, methane can also stimulate enterocinesia, to accelerate excrement discharge.Lignin, cellulose in pollen pini, hemicellulose
Equal insoluble diedairy fibers have stronger water absorbing force and swellability, and are not easy microorganism in digestive ferment or enteron aisle by alimentary canal
Glycolysis can form more food residue and increase stool weight and volume, keep excrement soft, be easy to be discharged.Excrement weight
The increase of amount and volume mechanically can stimulate intestinal wall to cause awareness of defecation, accelerate intestines peristalsis, so as to shorten swill in intestines
By the time in road, the generation of constipation is prevented.
2. influencing to test on intestinal flora
2.1 material
Kunming mouse, the present composition, broken masson pine pollen, natural pollen pini, Escherichia coli culture medium (EMB culture
Base), enterococcus culture medium (EC culture medium), Bifidobacterium (BBL culture medium), Bacillus acidi lactici culture medium (MRS culture medium) etc..
2.2 method
After mouse adapts to raising 4d, start formal test.Healthy mice 40 are selected, 4 groups (every group 10) are randomly divided into,
It is respectively as follows: control group, broken masson pine pollen group, natural pollen pini group, present composition group.The stomach-filling of each test group difference accordingly by
Try object, control group stomach-filling same amount of normal saline.
Before stomach-filling and stomach-filling the 14th day, sterile collection fresh excrement sample 0.1-0.4g is put into dry sterilization after weighing
In bottle, with 1:100 ratio, add sterile water, uniform suspension be made, then successively 10 times be incremented by and be diluted to a series of different dilutions
Containing bacterium solution to 10-9, sample dilution processing is completed in 4h.According to the result of preliminary experiment, 3 suitable bacterium solution dilutions are selected,
Lml is taken respectively, and on each selective medium, each dilution sets two repetitions.After bacterium colony is grown, to 4 kinds of intestinal floras
It is analyzed, (loglO is as a result indicated with the logarithm of the bacterium colony in every gram of excrementnCFU/g).4 kinds of bacterium cultivate 48h at 37 DEG C
After count.Wherein, Bifidobacterium and lactobacillus Anaerobic culturel, the identification technology method of various bacterium: lactobacillus is microscopy G+, shape
The bacterium colony of state rule；Bifidobacterium is microscopy G+, the irregular bacterium colony of form；Enterococcus is microscopy G+, the irregular bacterium of form
It falls；Enterobacteria is atropurpureus with or without green metal gloss, microscopy G-Bacterium colony.
2.3 test results and analysis
Influence of 3 pollen pini of table to intestinal flora
Compared with Normal group, P*< 0.05, P**< 0.01；Compare P before and after stomach-filling#< 0.05, P##< 0.01
The above result shows that after mouse is continuously fed each tested material 14d, Bifidobacterium, lactobacillus in enteron aisle, large intestine
Advantageous variation has occurred in bacillus and enterococcus quantity to some extent.I.e. Bifidobacterium, lactobacillus have apparent increase trend,
And Escherichia coli, enterococcus have apparent reduction trend.Do not gavage before and after each flora stomach-filling of blank control group of tested material all without
The significance of difference.This phenomenon is the most it is apparent that the present composition.
Although aforementioned present invention composition is the experimental data of composition prepared by embodiment 4, but invention of the invention
People has carried out above-mentioned reality as tested material to broken masson pine pollen in other embodiments 5- embodiment 10 and natural pine pollen composition
It tests, the results show that almost the same with the trend of above-mentioned data, this specification selection is experiment effect it is still further preferred that embodiment 4
Portfolio ratio.
Survive a large amount of bacterium in human body intestinal canal, these bacteriums form a complicated microecosystem, enterobacteriaceae
For group by forming to the beneficial and harmful two major classes of human health, Bifidobacterium and lactobacillus are that beneficial microorganism represents, and can be pressed down
The undue growth of pathogen processed is bred, and immunity of organisms is enhanced.And enterococcus and Escherichia coli are considered as normal intestinal flora
Structure is the representative of harmful bacteria to the important warning factor for being unfavorable for the transformation of body health direction.The extraordinary increasing of harmful bacteria quantity
Add and may cause certain intestines problems, therefore the normal environment of the Tiny ecosystem between maintenance intestinal flora and human health are closely related
Also most important.In experiment, the situation of change of the above-mentioned four major class intestinal flora of the mouse of the corresponding tested material of stomach-filling is to being conducive to
The direction of its health is developed.Especially the present composition has obvious inhibiting effect to pernicious bacteria, has growth-promoting to profitable strain
Effect.This may can generate a large amount of organic acid with the participation of the numerous microorganisms during the fermentation of dietary fiber in pollen pini,
PH value in enteron aisle is reduced, to inhibit the growth and breeding of pathogenic bacteria related.
Claims (5)
1. improving the pine pollen composition of gastrointestinal bacterial flora or relax bowel and defecation, it is characterised in that: it is comprising following weight proportion
The preparation of suitable clinical use that is prepared plus pharmaceutically acceptable auxiliary material or complementary ingredient of active constituent:
12 parts of broken masson pine pollen, 16 parts of natural pollen pini.
2. the pine pollen composition according to claim 1 for improving gastrointestinal bacterial flora or relax bowel and defecation, it is characterised in that: institute
State natural pollen pini be masson pine, Chinese pine or other belong to one of pollen or a variety of.
3. the pine pollen composition according to claim 1 or 2 for improving gastrointestinal bacterial flora or relax bowel and defecation, feature exist
In: the broken masson pine pollen is the pollen pini of 95% or more sporoderm-broken rate.
4. the medicine that the described in any item pine pollen compositions of claims 1 to 3 improve gastrointestinal bacterial flora or relax bowel and defecation in preparation
Purposes in object or health care product.
5. purposes according to claim 4, the relax bowel and defecation refers to enhancing WeiDongLi Capsule, promotes gastric emptying or promotes enteron aisle
It wriggles, the improvement gastrointestinal bacterial flora, which refers to, improves micro ecology of gastrointestinal tract environment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510471077.1A CN104997816B (en) | 2015-08-04 | 2015-08-04 | Improve the pine pollen composition and application thereof of gastrointestinal function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510471077.1A CN104997816B (en) | 2015-08-04 | 2015-08-04 | Improve the pine pollen composition and application thereof of gastrointestinal function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104997816A CN104997816A (en) | 2015-10-28 |
| CN104997816B true CN104997816B (en) | 2019-01-25 |
Family
ID=54370856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510471077.1A Active CN104997816B (en) | 2015-08-04 | 2015-08-04 | Improve the pine pollen composition and application thereof of gastrointestinal function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104997816B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105918731A (en) * | 2016-05-16 | 2016-09-07 | 合肥睿联生物科技有限公司 | Squid bone functional beverage with gastrointestinal tract adjusting function and preparing method thereof |
| CN109497483A (en) * | 2018-01-26 | 2019-03-22 | 中国科学院烟台海岸带研究所 | One kind is containing phycocyanin and pine pollen composition and its preparation and application |
| RU2713175C1 (en) * | 2019-02-04 | 2020-02-04 | Виктор Анатольевич Маткевич | Acid-mineral composition and enteral solution by matkevich for lavage of gastrointestinal tract and/or correction of homeostasis disorders |
| CN110089708A (en) * | 2019-05-16 | 2019-08-06 | 郝景龙 | Bi-component broken masson pine pollen |
| CN110122887A (en) * | 2019-06-03 | 2019-08-16 | 中国农业科学院农产品加工研究所 | Improve the dietary fiber chewable tablets and preparation method thereof of gastrointestinal function |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101237215B1 (en) * | 2011-02-15 | 2013-02-26 | 조신영 | Phamaceutical composition for prevention or treatment of enteritis |
-
2015
- 2015-08-04 CN CN201510471077.1A patent/CN104997816B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 松花粉作为保健食品的优势和特点;石丽花等;《农业工程技术（农产品加工业）》;20081231(第1期);第20-24页，尤其是第23页左栏第4-5段，20页左栏第4段 |
| 松花粉破壁前后显微形态和营养成分的研究;赵霖等;《营养学报》;20011231;第23卷(第2期);第153-156页，尤其是第155页右栏第3段 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104997816A (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095698B (en) | Use of Clostridium Butyricum for preventing and treating foetid faeces toxin syndrome and disease | |
| CN104997816B (en) | Improve the pine pollen composition and application thereof of gastrointestinal function | |
| Grieshop et al. | Oral administration of arabinogalactan affects immune status and fecal microbial populations in dogs | |
| Liu et al. | Microbiota populations and short-chain fatty acids production in cecum of immunosuppressed broilers consuming diets containing γ-irradiated Astragalus polysaccharides | |
| AU2016408376B2 (en) | Composition of probiotics and digestive enzymes and method of preparing and using the same | |
| CN103908585B (en) | For the probiotics fermention compositions of prevention and therapy constipation | |
| DE102006062250A1 (en) | Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort | |
| CN108741083A (en) | Promote the neutral human milk oligosaccharides of beneficial bacteria growth | |
| JPS60149527A (en) | Deodorant in living body | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN103446552B (en) | For the fermentation composition of prevention and therapy digestive system disease | |
| CN115838675B (en) | Lactobacillus rhamnosus and composition and application thereof | |
| US9993498B2 (en) | Method for the prevention and treatment of gastrointestinal distress in horses and other species | |
| US10548917B2 (en) | Supplement for the prevention and treatment of gastrointestinal distress in horses and other species | |
| CN107427697A (en) | Treatment diarrhoea and the method for promotion intestinal health in non-human animal | |
| CN101849969A (en) | Application of butyric acid producing beneficial bacterium in preparing preparation for preventing and treating severe disease gut barrier injury and post-injury complication | |
| WO2024149132A1 (en) | Probiotic protein multivitamin and preparation method therefor | |
| US20040120963A1 (en) | Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same | |
| Moise | The Gut Microbiome: Exploring the Connection between Microbes, Diet, and Health | |
| CN115252671B (en) | Application of prickly pear anthocyanins in the preparation of products regulating intestinal flora | |
| Sharma et al. | Influence of feeding crimped kernel maize silage on the course of subclinical necrotic enteritis in a broiler disease model | |
| US20110212881A1 (en) | Aleurone as a prebiotic fiber for improved intestinal health | |
| Sabater-Molina et al. | Effects of fructooligosaccharides on cecum polyamine concentration and gut maturation in early-weaned piglets | |
| Hosseintabar et al. | Is the amount of l-carnitine and methionine-lysine affect on the microbial flora of broiler cecum | |
| Poeikhampha et al. | Effect of sodium gluconate on pH value, ammonia and short chain fatty acids concentration in batch culture of porcine cecal digesta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20181219 Address after: 611130 Factory Building No. 11 and No. 12, No. 388 Rongtai Avenue, Chengdu Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant after: Chengdu universal drug development Co., Ltd. Address before: 610041 Xiaojiahe Street 99, Chengdu High-tech Zone, Sichuan Province Applicant before: Chengdu Purification Technology Development Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |